Yes. Trials show GLP-1 medications work about equally well for women and men, with average loss of about 15% on semaglutide and up to about 22.5% on tirzepatide in their trials.
That helps explain why GLP-1s are the most discussed weight loss treatment among women in 2026. For women whose weight has resisted dieting, particularly after pregnancy, during perimenopause or with PCOS, these drugs target the biology that makes losing weight hard.








